Symbol
| LRP6
| contributors: mct - updated : 02-06-2017
|
HGNC name
| low density lipoprotein receptor-related protein 6
|
HGNC id
| 6698
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
in leukemia, by hypermethylation | tumoral
|  
|  
| --low
|  
|
sufficient to inhibit breast cancer tumorigenesis | constitutional
|  
|  
| --over
|  
|
colocalizes with PDGFRB and is expressed abundantly in atherosclerotic lesions ( | constitutional
|  
|  
|  
| loss of function
|
in hyperlipidemia | |
Susceptibility
|
to premature coronary artery disease |
Variant & Polymorphism
other
| LRP6R611C mutation with a dominant-negative effects on the inhibition of PDGFRB, linked to a form of premature coronary artery disease |
|
|
Candidate gene
| plausible candidate genes for SHFM |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | reproductive | breast | |
potential therapeutic target in breast cancer, and introduce Mesd (LRP6 antagonist) as a promising antitumor agent for treating breast cancer subtypes with Wnt activation at the cell surface | metabolism | lipid | | |
potential target for development of novel therapeutics in hyperlipidemia |
| | |
| in Lrp6 mutant mice, the mechanism of birth defect prevention by Folic acid supplementation (reduction of neural tube defects occurrence by amelioration versus increased embryonic loss) can vary not only with the genes associated with increased risk, but also with the type of mutation within those genes (i.e. loss or gain of function ) |